The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Did CANF Stock Soar 40% In Pre-Market Today?
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.